Table 1 Baseline demographics
Variable | Placebo (n = 214) | Low dose | 600 mg q4w (n = 106) | 2,000 mg q4w (n = 214) | ||
|---|---|---|---|---|---|---|
125 mg q4w (n = 58) | 375 mg q12w (n = 58) | Total (n = 116) | ||||
Age (years), mean ± s.d. | 69.8 ± 6.6 | 70.4 ± 6.8 | 70.3 ± 6.8 | 70.4 ± 6.8 | 69.7 ± 6.7 | 69.4 ± 7.1 |
Femalea, n (%) | 106 (49.5) | 28 (48.3) | 26 (44.8) | 54 (46.6) | 55 (51.9) | 112 (52.3) |
Country, n (%) | ||||||
USA | 117 (54.7) | 31 (53.4) | 30 (51.7) | 61 (52.6) | 56 (52.8) | 119 (55.6) |
Australia | 6 (2.8) | 2 (3.4) | 2 (3.4) | 4 (3.4) | 2 (1.9) | 7 (3.3) |
Germany | 18 (8.4) | 4 (6.9) | 9 (15.5) | 13 (11.2) | 10 (9.4) | 21 (9.8) |
Spain | 20 (9.3) | 8 (13.8) | 4 (6.9) | 12 (10.3) | 12 (11.3) | 13 (6.1) |
France | 19 (8.9) | 5 (8.6) | 5 (8.6) | 10 (8.6) | 7 (6.6) | 17 (7.9) |
Italy | 9 (4.2) | 1 (1.7) | 3 (5.2) | 4 (3.4) | 5 (4.7) | 9 (4.2) |
Japan | 3 (1.4) | 3 (5.2) | 2 (3.4) | 5 (4.3) | 6 (5.7) | 5 (2.3) |
Poland | 14 (6.5) | 3 (5.2) | 3 (5.2) | 6 (5.2) | 7 (6.6) | 14 (6.5) |
Sweden | 8 (3.7) | 1 (1.7) | 0 | 1 (0.9) | 1 (0.9) | 9 (4.2) |
Raceb, n (%) | ||||||
Asian | 5 (2.3) | 3 (5.2) | 2 (3.4) | 5 (4.3) | 6 (5.7) | 6 (2.8) |
White | 201 (93.9) | 53 (91.4) | 53 (91.4) | 106 (91.4) | 98 (92.5) | 203 (94.9) |
Education (years), mean ± s.d. | 14.8 ± 3.7 | 14.4 ± 4.1 | 13.9 ± 3.2 | 14.2 ± 3.7 | 14.2 ± 3.7 | 14.3 ± 3.7 |
AD medication use, n (%) | 139 (65.0) | 38 (65.5) | 37 (63.8) | 75 (64.7) | 69 (65.1) | 137 (64.0) |
ApoE ε4 statusc, n (%) | ||||||
Carrier | 157 (73.4) | 35 (60.3) | 43 (74.1) | 78 (67.2) | 66 (62.3) | 160 (74.8) |
Noncarrier | 54 (25.2) | 21 (36.2) | 15 (25.9) | 36 (31.0) | 40 (37.7) | 54 (25.2) |
Clinical stage, n (%) | ||||||
MCI | 98 (45.8) | 25 (43.1) | 31 (53.4) | 56 (48.3) | 51 (48.1) | 98 (45.8) |
Mild AD dementia | 116 (54.2) | 33 (56.9) | 27 (46.6) | 60 (51.7) | 55 (51.9) | 116 (54.2) |
